Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Will J&J announce a new Phase III trial for Rybrevant in colorectal cancer by mid-2025?  | Binary | 3 | 3 months ago | ||
Will Rybrevant show a higher overall survival rate in EGFR-mutated lung cancer patients by end of 2024? | Binary | 2 | 3 months ago | ||
Will Rybrevant be FDA approved for metastatic colorectal cancer by mid-2025? | Binary | 2 | 3 months ago | ||
What will be the overall response rate of Rybrevant in metastatic colorectal cancer patients by end of 2024? | Categorical | 2 | 3 months ago | ||
How many new indications will Rybrevant be FDA approved for by end of 2025? | Categorical | 2 | 3 months ago | ||
What will be the market share of Rybrevant in EGFR-mutated lung cancer treatment by end of 2025? | Categorical | 2 | 3 months ago |